ArticleWorld journal of urology2021
Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Focal therapy using a novel cooled laser device for prostate cancer: early trial results.BJU international · 2026Trial
- Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).BMC urology · 2024Trial
- MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Review
- Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate international · 2026Review
- Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Translational andrology and urology · 2025Review
- Incidence of ideal candidates for focal therapy: A scoping study following the FALCON Consensus Statements.BJUI compass · 2025Article
- Article
- Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.The world journal of men's health · 2025Article
- Advances in irreversible electroporation for prostate cancer.Discover oncology · 2024Review
- Win ratio analysis of short-term clinical outcomes of focal therapy and robot-assisted radical prostatectomy for the patients with localized prostate cancer.Scientific reports · 2024Article
- Review
- Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer.The world journal of men's health · 2024Article
- Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art.Journal of personalized medicine · 2024Review
- One-year Follow-up Results of Transperineal Biopsy For Patients Undergoing Irreversible Electroporation Treatment in Localized Prostate Cancer.Urology research & practice · 2023Article
- Review
- Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes.Prostate cancer and prostatic diseases · 2023Review
- Topography of Prostate Cancer Recurrence: A Single-centre Analysis of Salvage Radical Prostatectomy Specimens and Implications for Focal Salvage Treatments.European urology open science · 2023Article
- Modern paradigms for prostate cancer detection and management.The Medical journal of Australia · 2022Review
- Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.Investigative and clinical urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveTo assess the safety, oncological and quality-of-life (QoL) outcomes of focal ablation of apical prostate cancer (PCa) lesions with irreversible electroporation (IRE).
methodsPatients were included in the study if they had a PCa lesion within 3 mm of the apical capsule treated with IRE. The IRE procedure was performed in our institution by a single urologist. The QoL and functional data was collected prospectively from patients who provided consent using the Expanded Prostate Cancer Index Composite (EPIC). Oncological follow up included 3-month PSA levels, mpMRI at 6 months and transperineal biopsy at 1-year post treatment.
resultsA total of 50 patients had apical PCa lesions treated between February 2013 and September 2018. Median follow-up was 44 months. There were no Clavien-Dindo grade 3 events or higher. No perioperative complications were recorded. No significant difference was observed in the EPIC urinary or bowel QoL domain between baseline and 12-month post-treatment. One patient (2%) required one pad per day for urinary incontinence 12-month post-treatment. There was a small but significant decline in EPIC sexual QoL (65 at baseline and 59 at 12-month post-IRE). Of patient's potent pre-treatment, 94% remained potent after treatment. The median PSA nadir decreased by 71% (6.25-1.7 ng/mL). Only one patient (2.5%) had in-field residual disease on repeat biopsy.
conclusionFocal ablation using IRE for PCa in the distal apex appears safe and feasible with acceptable early QoL and oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.